158 articles · 20 / page
The Navigate-Kidney trial demonstrates that community health worker support significantly improves interdialytic weight gain, dialysis adherence, and patient activation among Hispanic and Latino individuals on hemodialysis, addressing criti
This article explores a novel 3-year prognostic score for Fabry Disease cardiomyopathy, integrating CMR-derived T1 values, LV mass, and LGE extent to predict adverse events, emphasizing the negative predictive value of normal T1 mapping.
A large-scale multicenter study reveals that hospitals with higher utilization rates of continuous kidney replacement therapy (CKRT) achieve significantly lower 90-day mortality for critically ill AKI patients compared to low-utilization ce
A large-scale multicenter study reveals that 46.6% of severe AKI survivors in India and Southeast Asia experience major adverse kidney events (MAKE) within two years, with mortality and new-onset chronic kidney disease being the primary dri
A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kid
A 15-year cohort study reveals that obese ICU patients requiring kidney replacement therapy face nearly triple the mortality rate of those who do not, despite a declining trend in overall acute kidney injury incidence within this high-risk
A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP
This randomized controlled trial demonstrates that a lower bicarbonate replacement fluid (22 mmol/l) provides superior acid-base stability compared to a higher concentration (30 mmol/l) during CVVH with citrate anticoagulation, significantl
This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electr
A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and qu
A meta-analysis of 14 matched-control studies (n=1,058,109) finds that survivors of in-hospital AKI face higher long-term mortality, greater subsequent dialysis need, and elevated risk of CKD versus matched controls.
A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active
In the phase 3 VALIANT trial, pegcetacoplan, a C3/C3b inhibitor, produced a large, rapid reduction in proteinuria versus placebo at 26 weeks in patients with C3 glomerulopathy or primary immune‑complex MPGN, with an acceptable short-term sa
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a
In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or th
This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF
This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.
A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (<25 and <20 ml/min/1.73 m2) increased cardiovascular risk nearly twofold, but SGLT2 inhibitors reduced that risk and retained benefit regardl
An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart fai
A translational study links hyperglycaemia-driven PAD4-dependent neutrophil extracellular trap (NET) formation and inflammasome activation to cardiac and renal inflammation, fibrosis, and heart failure in experimental diabetes—suggesting no
Open language-specific specialty feeds and department pages.